The FDA has released a new draft guidance, Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs. The document is set to replace the 2023 version.
- Does Drug Discovery Anticipate Delivery?
- Antibody–Oligonucleotide Conjugates, Part 3: Analytical Control
- Designing For Precision: How Delivery Is Shaping Cancer Treatment
- Antibody–Oligonucleotide Conjugates, Part 2: Manufacturing
- Intratumoral Treatment Of Cancer: After Many Prior Attempts, Has The Time Finally Come?
- Crossing The Uncrossable: Skin Biology For The Delivery Of Peptide And Protein Therapeutics
- When The Adhesive Becomes The Drug Delivery System
- Antibody–Oligonucleotide Conjugates, Part 1: Approaching Your AOC Development Plan
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Turning A "Brick Dust" Compound Into A Clinically Viable Oral Formulation
Advanced wet milling and particle stabilization improve solubility, enhance bioavailability, and support scalable manufacturing for complex oral drug development programs.
-
Successful Tech Transfer Plans Ensured On-Time Launches
Successful technology transfers require proactive engineering and rigorous assessments to address equipment challenges, protect product integrity, and keep launches on schedule.
-
Managing Risks With Potent Pharmaceutical Products
Manufacturing potent medications safely requires specialized containment, toxicology expertise, and strict contamination controls to ensure compliance, product quality, and worker safety.
-
Is Your API Right For A Soft Gel Capsule?
Soft gel delivery systems can enhance bioavailability, enable controlled release, support combination dosing, and handle potent compounds while improving stability and patient adherence.
-
How A CDMO Overcomes Soft Gel Formulation Challenges
Softgel development demands careful control of shell properties, liquid fills, and stability. Overcoming formulation challenges improves drug delivery, bioavailability, and shelf life.
-
Ensuring Business Continuity In Your Pharmaceutical Commercial Supply
Drug shortages demand resilient supply chains and strategic partnerships. Learn how experienced manufacturers help mitigate risks and ensure reliable supply.
-
Oral Solutions & Suspensions: The Art Of Pharmacy
Oral liquid formulations improve accessibility and dosing flexibility. Learn how developers overcome stability, taste-masking, and manufacturing challenges.
-
Creating A New Dosage Form From An Approved Drug For A New Rare Disease
Advancing approved drugs into new indications requires smart formulation, strong quality controls, and regulatory expertise to overcome challenges and accelerate patient access.
-
10 Qualities Your CDMO Should Have For An Oral Dose Tech Transfer
Choose a manufacturing partner that supports every development phase with regulatory expertise, supply chain resilience, and formulation know-how.
-
Advancing The Development Of Syringe-Device Combinations
Defining the design for syringe-autoinjector pairings early, through shared compatibility testing, can reduce integration risk for high-viscosity biologics intended for self-administration at home.
TOM'S TAKES ON DRUG DELIVERY
TALKING WITH TOM VIDEOCASTS
DELIVERED BY DEGRAZIO
-
Container Closure Systems For Biosimilars: Is There Regulatory Difference?
In this article, Fran DeGrazio discusses the FDA’s draft guidance on container closure systems for biosimilar products. She highlights key takeaways and offers recommendations on implications that developers of biosimilar pharmaceutical products should consider in areas such as quality, testing, and documentation.
EDITORIAL COLLECTIONS KNOWLEDGE CENTER
Our Editorial Collections examine today’s biggest scientific, operational, and patient-centered drug delivery issues. These collections help companies navigate complex development decisions with in-depth analysis, real-world examples, and guidance from industry experts.

